Results 201 to 210 of about 9,167 (280)

Plasma Galectin-7 (Gal-7) and Galectin-8 (Gal-8) as Emerging Biomarkers in Psoriasis: Associations with Disease Activity and Metabolic Status. [PDF]

Metabolites
Nowowiejska-Purpurowicz J, Baran A, Hermanowicz JM, Sieklucka B, Pawlak K, Pawlak D, Flisiak I.   +6 more
europepmc   +1 more source

Impact of Isolation Techniques on the Content of Small Extracellular Vesicles

Journal of Extracellular Vesicles, Volume 15, Issue 6, June 2026.
ABSTRACT An important topic of discussion amongst the extracellular vesicle (EV) research field is which genetic materials are considered true constituents of EV cargo. What were once regarded as non‐EV components have now evolved to be potentially essential to EV composition, serving as key mediators in communication.
Yue Su, Kekoolani S. Visan, Sarah Voss, Marta Prieto‐Vila, Juntaro Matsuzaki, Jason Ying Kuen Chan, Judy Wai Ping Yam, Andreas Möller   +7 more
wiley   +1 more source

Maternal and placental galectins: key players in the feto-maternal symbiotic tango. [PDF]

Semin Immunopathol
Oravecz O, Xie Y, Balogh A, Posta M, Harms C, Farkas E, Borowski S, Szekeres-Barthó J, Than NG, Blois SM.   +9 more
europepmc   +1 more source

Plasma Galectin-4 and Charcot-Leyden Crystal Protein/Galectin-10 as Emerging Biomarkers of Metabolically Induced Inflammation in Patients with Psoriasis. [PDF]

Int J Mol Sci
Baran A, Nowowiejska J, Parzych J, Hermanowicz JM, Sieklucka B, Pawlak D, Flisiak I.   +6 more
europepmc   +1 more source

Inhibition of PLA2G15 Alleviates Palmitic Acid‐Induced Lysosomal Membrane Permeabilization in Human Nucleus Pulposus Cells During Intervertebral Disc Degeneration

JOR SPINE, Volume 9, Issue 2, June 2026.
LMP is responsible for lysosomal dysfunction in IDD. The lipid composition changes in the lysosomal membrane, mediated by PLA2G15, are the cause of LMP. The C/EBPα significantly promotes PLA2G15 expression under PA overload stress. Inhibition of PLA2G15 alleviates PA‐induced LMP by inhibiting the hydrolysis of lysosomal membrane phospholipids. ABSTRACT
Liqun Duan, Jiang Jiang, Shuangshuang Tu, Chuanfu Li, Yijun Dong, Yongjin Li, Wenzhi Zhang, Xi Chen   +7 more
wiley   +1 more source

Protecting the sugar coat on anti-tumor T cells to conceal destruction by tumor microenvironmental landmines. [PDF]

Mol Ther Oncol
Lau LS, Dimitroff CJ.
europepmc   +1 more source

The Economic Burden of Metabolic Dysfunction‐Associated Steatohepatitis (MASH) With Cirrhosis: A Systematic Review

Liver International Communications, Volume 7, Issue 2, June 2026.
ABSTRACT Background & Aims The clinical burden of metabolic dysfunction‐associated steatohepatitis (MASH) is substantial and there are no approved treatments for patients with cirrhosis. This systematic review aimed to better understand the economic burden in this population.
Jeffrey V. Lazarus, Caroline Freeman, Hannes Hagström, Mazen Noureddin, Riku Ota, Mary E. Rinella, Giada Sebastiani, Fotis Tefos, Zobair M. Younossi   +8 more
wiley   +1 more source

Galectins-1, -3 and -9 in leukemia: mechanistic insights and therapeutic translation. [PDF]

Front Immunol
Wang T, Zhang Y, Guo Y, Zhao M, Cai X, Feng S.   +5 more
europepmc   +1 more source

Prognostic Impact and Clinicopathological Significance of TIM‐3 and LAG‐3 Expressions in Laryngeal Squamous Cell Carcinoma

Laryngoscope Investigative Otolaryngology, Volume 11, Issue 3, June 2026.
ABSTRACT Introduction Research on immune checkpoint molecules is increasing, reflecting their critical role in cancer pathogenesis. While PD‐1, PD‐L1, and CTLA‐4 have been widely studied in head and neck cancers, outcomes remain unsatisfactory, highlighting the need for novel prognostic markers and therapeutic targets.
Fırat Tevetoğlu, Nil Çomunoğlu, Haydar Murat Yener   +2 more
wiley   +1 more source

Role of Galectin-1 in the Pathogenesis of Melanoma. [PDF]

J Cancer Sci Clin Ther
Kim G, Blackwell T, Banai K, Lin R, Chung J, Agrawal DK.   +5 more
europepmc   +1 more source